FDA granted Orphan Drug Designation to stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
FDA grants Orphan Drug Designation to iadademstat in SCLC
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
FDA approved Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA, and the UCLA Fielding School of Public Health, was awarded a $2.5 million grant from the Bristol Myers Squibb Foundation, an independent charitable organization, to spearhead a new initiative aimed at reducing disparities in lung cancer screening across Los Angeles County.
FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.
FDA’s cancer czar Richard Pazdur had a “silver anniversary” at the agency recently. So, he invited some guests—the commissioners he had reported to under the Democratic and Republican administrations.
Scemblix (asciminib) was granted accelerated approval by FDA for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
